eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | squamous cell carcinoma of head and neck |
| Comorbidity | C0007137|squamous cell carcinoma |
| Sentences | 200 |
| PubMedID- 21708009 | Conversely, no correlation was found between vegf and c-erbb-2 in squamous cell carcinoma of the head and neck [40], and there is little research on correlation of vegf and her-2/neu in colon cancer. |
| PubMedID- 25868613 | Many patients with squamous cell carcinoma of the head and neck (scchn) present with locally advanced disease, which is often associated with unsatisfactory outcomes despite innovative treatment approaches [1-3]. |
| PubMedID- 20623305 | Patients with advanced (stages iii and iv) squamous cell carcinoma of the head and neck treated at the netherlands cancer institute with concomitant chemoradiotherapy (ccrt) were invited to participate in this randomized controlled clinical trial. |
| PubMedID- 26090365 | Van de wiele (47) and moon (126) presented the available data in patients suffering from squamous cell carcinoma of the head and neck, lung carcinoma, esophageal carcinoma, and gynecological malignancies. |
| PubMedID- 21285536 | Cetuximab, a chimeric mouse-human igg1 targeting epidermal growth factor receptor (egfr), is approved for use in the eu and us as a treatment for colorectal cancer and squamous cell carcinoma of the head and neck.12 a high prevalence of hypersensitivity reactions to cetuximab has been reported in some areas of the us. |
| PubMedID- 20592893 | squamous cell carcinoma of the head and neck (scchn) is the fifth most common cancer worldwide and accounts for 3.5% of the cancers registered in korea during 2001 (1). |
| PubMedID- 20379402 | squamous cell carcinoma of the head and neck (scchn) accounted for 3.5% of all the registered cancers in korea during 2001 (1). |
| PubMedID- 21102583 | squamous cell carcinoma of the head and neck (hnscc) is the fifth most common cancer worldwide (wong et al, 1996). |
| PubMedID- 24932237 | Globally, smoking habit and alcohol consumption are considered to be risk factors, resulting in individuals exhibiting squamous cell carcinoma of the head and neck. |
| PubMedID- 24072600 | Cin85 was reported to be highly expressed in human squamous cell carcinoma of the head and neck and in cervical carcinoma and this overexpression was significantly correlated with advanced clinical stages of disease [30,31]. |
| PubMedID- 21245614 | Abdulla et al64 observed that plasma zinc was decreased and the copper:zinc ratio in the plasma was significantly higher in patients with squamous cell carcinoma of the head and neck in comparison to healthy controls. |
| PubMedID- 25674742 | squamous cell carcinoma of the head and neck (scchn) is the sixth most frequently occurring malignancy worldwide, and is a serious global health threat.1 despite the improvements and refinements in surgical, chemotherapeutic, and radiotherapeutic regimens that have occurred in the past few decades, the survival quality and ultimate prognosis remain unsatisfactory. |
| PubMedID- 23236400 | Cancer types were classified as breast cancer, liver cancer (hepatocellular carcinoma and liver cancer), squamous cancer (squamous cell carcinoma of head and neck, cervical squamous cell carcinoma, and oral squamous cell carcinoma), and other cancers (gastric cancer and bladder cancer). |
| PubMedID- 24061161 | [27] found that in patients with squamous cell carcinoma of the head and neck, those with lower pretreatment adc values were more likely to respond to chemoradiation therapy, assessed by clinical, radiologic and pathologic parameters. |
| PubMedID- 21559372 | squamous cell carcinoma of the head and neck (scchn) is the seventh most common cancer worldwide [1]. |
| PubMedID- 24147019 | When the bax gg genotype was taken as the reference group, no association was found between the aa and ag variant genotypes with squamous cell carcinoma of the head and neck (scchn) risk [36]. |
| PubMedID- 24612587 | squamous cell carcinoma of head and neck (hnscc) is a heterogeneous disease[1]. |
| PubMedID- 21586140 | By contrast, the variant allele was associated with favorable os in patients with stage iv squamous cell carcinoma of the head and neck (scchn) treated with cisplatin-based chemotherapy or rct[12]. |
| PubMedID- 22485156 | Then, we tested whether preincubation with cxcl12 before adding [18f]msx-122f blocked binding to cxcr4 in the cxcr4-positive metastatic squamous cell carcinoma of head and neck (scchn) cells that we established from a poorly metastatic parental cell line by four rounds of in vivo selection using a lymph node metastatic xenograft mouse model. |
| PubMedID- 21326242 | squamous cell carcinoma of the head and neck (hnscc) is a heterogeneous disease involving multiple anatomical localisations. |
| PubMedID- 22180675 | More recently, cetuximab was approved for use in squamous cell carcinoma of the head and neck. |
| PubMedID- 25734919 | squamous cell carcinoma of the head and neck (hnscc) is the sixth most frequent type of cancer. |
| PubMedID- 21698152 | Ccr7 is highly expressed in non-small cell lung cancer (nsclc), breast cancer, and squamous cell carcinoma of the head and neck and is responsible for mediating metastasis in certain cancer cells lines [6]–[15]. |
| PubMedID- 21188107 | Patients with stage iii or iv, nonmetastatic, measurable squamous cell carcinoma of the head and neck (scchn) were eligible. |
| PubMedID- 21439046 | Criteria for inclusion were tumor histology with a squamous cell carcinoma of the head and neck, and regular follow-up examinations with a minimum follow-up time of 12 months, including clinical and radiological (ct) controls. |
| PubMedID- 20714355 | squamous cell carcinoma of the head and neck (hnscc) is diagnosed in over 500,000 patients worldwide each year, accounting for 5% of all malignancies.1 in the united states, the estimated incidence was 45,660 new cases and 11,210 deaths in 2007. |
| PubMedID- 22590529 | Hnssc (squamous cell carcinoma of the head and neck) xenotransplanted severe combined immunodeficient (scid) mice were treated with radioimmunotherapy against epcam positive cells and biodistribution of epcam-directed monoclonal antibodies were investigated in epcam-transgenic mouse models [17], [18]. |
| PubMedID- 22214534 | A prognostic value has been assigned to changes in syndecan-1 expression in several cancer types, including breast, colorectal, gastric, pancreatic, prostate, lung, endometrial, and ovarian cancers, as well as squamous cell carcinoma of the head and neck and multiple myeloma [6,7]. |
| PubMedID- 24665442 | All forty two patients with locally advanced squamous cell carcinoma of the head and neck were treated with previously mentioned protocols. |
| PubMedID- 21483822 | Ec: esophageal cancer; hcc: hepatocellular carcinoma; scchn: squamous cell carcinoma of the head and neck; pcr-rflp: polymerase chain reaction-restriction fragment length polymorphism; pcr–ldr: polymerase chain reaction–ligation detection reaction; fuorescence: labeled hybridization probes; pb, population based; hb, hospital based. |
| PubMedID- 25929687 | squamous cell carcinoma of the head and neck (scchn) is the sixth most common cancer and also the most common tumor type in the head and neck region. |
| PubMedID- 26034394 | Patients were eligible for the study if they had squamous cell carcinoma of the head and neck (primary tumour), and if they received high-dose cisplatin chemotherapy (80 or 100 mg/m2) and concurrent radiotherapy as therapeutic conduct. |
| PubMedID- 21912620 | Based on these observations, we hypothesized that c225 can enhance cytotoxicity with the parpi abt-888 in um-scc1, um-scc6, and fadu cells, which are well characterized, egfr overexpressing, representative squamous cell carcinoma of the head and neck [17]–[20]. |
| PubMedID- 24577117 | Tumor human papillomavirus (hpv) status is an important prognostic factor in locoregionally advanced squamous cell carcinoma of the head and neck (scchn). |
| PubMedID- 23150825 | Similarly, perez-soler et al., using an igg2 mouse monoclonal antibody, and modjtahedi et al., using an igg2 rat monoclonal antibody, targeted egfr in patients with lung cancer and squamous cell carcinoma of the head and neck without significant toxicity [55, 56]. |
| PubMedID- 25971451 | Patients with documented histologically proven squamous cell carcinoma of the head and neck planned for primary radical chemo-radiotherapy, with or without induction chemotherapy followed by radiotherapy with concomitant platinum based chemotherapy. |
| PubMedID- 24886289 | Fadd expression was associated with metastasis in squamous cell carcinoma of the head and neck [14] and poor prognosis in oral squamous cell carcinoma [15] and lung adenocarcinoma [16]. |
| PubMedID- 24760075 | Dysregulated notch signaling has been reported in many tumors [8], [11], [12] including cervical cancer [13], pancreatic cancer [14], squamous cell carcinoma of the head and neck [15], renal carcinoma [16], b- and t-cell–derived tumor cells of hodgkin, anaplastic large cell lymphoma [17], and invasive human pancreatic cancer [18]. |
| PubMedID- 20222943 | squamous cell carcinoma of the head and neck (scchn) are aggressive tumours, which are still associated with poor prognosis despite improvements in surgical and radiotherapeutic techniques [1]. |
| PubMedID- 22738713 | Egfr is almost universally expressed in squamous cell carcinoma of head and neck (scchn), and high levels of expression have been correlated with a poor clinical prognosis [1]. |
| PubMedID- 25926743 | It is also used with radiation therapy, as a first-time treatment for advanced squamous cell carcinoma of the head and neck. |
| PubMedID- 24598405 | squamous cell carcinoma of the head and neck region (hnscc) makes up approximately 5% of all solid cancers in europe and north america. |
| PubMedID- 24818750 | Various treatment strategies are used to improve outcome in patients with squamous cell carcinoma of the head and neck. |
| PubMedID- 22675506 | squamous cell carcinoma of the head and neck region (hnscc) is the sixth most prevalent cancer worldwide, accounting for 3% of all cancers [1]. |
| PubMedID- 24722213 | There were 67 patients with primary squamous cell carcinoma of the head and neck in this cohort who met inclusion criteria and for whom we had complete e-cadherin, beta-catenin and egfr expression data. |
| PubMedID- 21969775 | Compared in 78 patients with stages ii–iv squamous cell carcinoma of the head and neck, gross tumor volume (gtv) delineated on ct with five pet-based gtvs obtained by visual interpretation (gtv vis ), applying an isocontour of a standardized uptake value of 2.5 (gtvsuv), using a fixed threshold of 40% (gtv40%) and 50% (gtv50%) of the maximum signal intensity, and applying an adaptive threshold based on the signal-to-background ratio (gtvsbr). |
| PubMedID- 22684281 | Cetuximab, a chimeric mouse-human igg1 targeting egfr, is approved for use in the eu and us as a treatment for colorectal cancer and squamous cell carcinoma of the head and neck. |
| PubMedID- 22523600 | squamous cell carcinoma of the head and neck (scchn) typically presents in advanced stages and is associated with poor survival and high recurrence and second primary tumor rates [1]. |
| PubMedID- 23053322 | The study group comprised 20 patients (16 men, 4 women) aged between 52 and 81 years (median 64 years) with histologically proven squamous cell carcinoma of the head and neck region. |
| PubMedID- 24260099 | Abbreviations: scchn, squamous cell carcinoma of the head and neck; hcc, hepatocellular carcinoma; all, acute lymphoblastic leukemia; pb, population based; hb, hospital based; hwe, hardy-weinberg equilibrium. |